Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Publication | Open Access

DOI Full Paper Access

218

Citations

References

2015

Year

Joan T. Merrill, Ronald van Vollenhoven, Jill P. Buyon, Richard Furie, William Stohl, MA Morgan-Cox, C. Dickson, Pamela W. Anderson, Calvin Lee, Berclaz P-Y.,

Annals of the Rheumatic Diseases